Prospective Cohort Study With Fixed-Duration Ibrutinib + Venetoclax (I+V) First-Line Treatment in Patients with Chronic Lymphocytic Leukemia in a Real-World Setting
- Promotore
- Janssen Global Medical Affairs
- Acronimo
- REALITY-WW
- Struttura
- Ematologia
- Sperimentatore principale
- Catania Gioacchino
- Stato arruolamento
- Arruolamento in corso